The ethanol extract of FCI potentially counters bone loss in mice by enhancing osteoblast proliferation and differentiation, facilitated by multiple bioactive compounds.
In this study, the researchers scrutinized the antiosteoporosis potential of the ethanol extract of FCI in mice experiencing bone loss due to ovariectomy, a process likened to human menopause. In the process, the antiosteoporosis fraction derived from FCI was isolated and cleansed using a technique known as high-speed countercurrent chromatography, which resulted in the successful isolation of the principle bioactive compounds.
The researchers found that, among the separations, the ethyl acetate fraction exhibited remarkable antiosteoporosis activity. Upon further analysis, the foremost compounds were identified as acacetin, apigenin, luteolin, and linarin. Furthermore, these compounds were found to stimulate the proliferation and differentiation of osteoblasts - the cells responsible for bone formation. The process was potentially mediated by the activation of the AKT signaling pathway and the upregulation of certain genes such as Runx2, OCN, OPN, and COL I. The collective efforts of these bioactive compounds played a crucial role in the observed antiosteoporosis effects, suggesting that the effectiveness of FCI is not reliant on a single component, but an ensemble of elements working in tandem.
